Genmab Regains Rights to HuMax-CD4

COPENHAGEN, June 29 /PRNewswire/ --

- Plans Expanded Cancer Development and UniBody for HIV

- Summary: Genmab has regained rights to HuMax-CD4 from Merck Serono and
plans to expand development in cancer and create a UniBody for HIV.

Genmab A/S (CSE: GEN) announced
today it has regained all rights to the HuMax-CD4(R) (zanolimumab) antibody
from Merck Serono S.A. Genmab plans to continue moving development of
HuMax-CD4 forward in the existing non-cutaneous T-cell lymphoma and cutaneous
T-cell lymphoma clinical programs and expand development into earlier stage
patients in combination with PUVA as well as other combinations with approved
therapies for CTCL.

In addition, Genmab is making plans to develop a UniBody(TM) targeting
the CD4 receptor. HuMax-CD4 binds the CD4 molecule with very high affinity
and effectively blocked and neutralized infection of a broad panel of HIV-1
viruses isolated from infected individuals. Laboratory studies in an
immunodeficient (SCID) mouse model, where animals were reconstituted with
human blood cells, showed HuMax-CD4 to effectively block HIV-1 replication
and reduce depletion of CD4+ T-cells by the virus. A UniBody targeting CD4
represents a promising drug candidate that may prevent or slow HIV-1
infection and AIDS and spare T-cells.

Worldwide rights to HuMax-CD4 were previously licensed to Merck Serono
S.A. in August 2005. Regaining rights to HuMax-CD4 will not influence
Genmab's financial guidance for 2007.

"We are very enthusiastic about having HuMax-CD4 back in the hands of
Genmab's experienced clinical development team who will work diligently to
move the program forward. HuMax-CD4 is a nice fit with the rest of Genmab's
pipeline and may provide us with an additional commercial opportunity to move
the company forward into the sales and marketing arena," said Lisa N.
Drakeman, Ph.D., Chief Executive Officer of Genmab. "If we ultimately build a
sales force for HuMax-CD20, we would be in a position for this same sales
force to market HuMax-CD4."

Conference Call          
                                                           
    Genmab will hold a conference call about the news today, Friday, 
    June 29, 2007 
 
    at:                                                                             
    
    3:30 PM CEST                                                                    
    2:30 PM BST                                                                     
    9:30 AM EDT                                                                     

    The dial in numbers are as follows:                                             

    +1-800-479-9001 (in the US)                                                     
    +1-719-457-2618 (outside the US)                                                

    The conference call will be held in English.                                    

    To listen to a live webcast of the call please visit:                           
    https://cis.premconf.com/sc/scw.dll/usr?cid=vlllrznlmslvsmwmm



About Genmab A/S

Genmab A/S is a biotechnology company that creates and develops human
antibodies for the treatment of life-threatening and debilitating diseases.
Genmab has numerous products in development to treat cancer, infectious
disease, rheumatoid arthritis and other inflammatory conditions, and intends
to continue assembling a broad portfolio of new therapeutic products. In
addition, Genmab has developed UniBody(TM), a new proprietary technology that
creates a stable, smaller antibody format. Genmab has operations in Europe
and the US. For more information about Genmab, visit www.genmab.com.

This press release contains forward looking statements. The words
"believe", "expect", "anticipate", "intend" and "plan" and similar
expressions identify forward looking statements. Actual results or
performance may differ materially from any future results or performance
expressed or implied by such statements. The important factors that could
cause our actual results or performance to differ materially include, among
others, risks associated with product discovery and development,
uncertainties related to the outcome and conduct of clinical trials including
unforeseen safety issues, uncertainties related to product manufacturing, the
lack of market acceptance of our products, our inability to manage growth,
the competitive environment in relation to our business area and markets, our
inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab
is not under an obligation to up-date statements regarding the future
following the publication of this release; nor to confirm such statements in
relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R);
HuMax-CD20(R);

HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM);
HuMax-CD38(TM);

HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.

Contact: Helle Husted, Sr. Director, Investor Relations, 
T: +45-33-44-77-30, M: +45-25-27-47-13, E: hth@genmab.com

Stock Exchange Release no. 32/2007